COVID-19 and Gut Injury

Area of Science:

• Gastroenterology
• Virology
• Immunology

Background:

• COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of deaths globally.
• Males and aged individuals exhibit higher susceptibility and severity of COVID-19.
• Gastrointestinal (GI) symptoms and gut microbiota alterations are common in COVID-19 patients.

Purpose of the Study:

• To review mechanisms of COVID-19-induced gut injury.
• To explore the relationship between COVID-19 and inflammatory bowel disease (IBD).
• To summarize current and potential therapeutics for GI manifestations of COVID-19.

Main Methods:

• Review of current literature on COVID-19 pathogenesis and GI involvement.
• Analysis of the role of angiotensin-converting enzyme 2 (ACE2) in SARS-CoV-2 infection of the GI tract.
• Summary of therapeutic strategies targeting GI symptoms.

Main Results:

• The primary mechanism of COVID-19-induced gut injury involves SARS-CoV-2 binding to ACE2 receptors in the GI tract.
• Despite being an inflammatory disorder, IBD patients do not show an increased risk for COVID-19.
• Existing treatments like antivirals and monoclonal antibodies reduce viral load and recovery time.

Conclusions:

• COVID-19 significantly impacts the gastrointestinal tract through mechanisms involving ACE2 receptor binding.
• Gut microbiota dysbiosis is a key feature of COVID-19-related gut injury.
• Therapeutics including probiotics, ACE2 inhibitors, and nutritional supplements offer potential for managing GI symptoms in COVID-19.